Psychotropic drugs, torsade de pointes and sudden death

Acta Psychiatrica Scandinavica

Volumn 111, Issue 3, 2005, Pages 169-170

  Taylor, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUTYROPHENONE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; THIORIDAZINE;

CARDIOTOXICITY; EDITORIAL; HUMAN; LONG QT SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; SUDDEN DEATH; TORSADE DES POINTES;

DEATH, SUDDEN; HUMANS; LONG QT SYNDROME; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; TORSADES DE POINTES;

EID: 14844314433     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2004.00507.x     Document Type: Editorial

References (19)

1. JUSTO D, PROKHOROV V, HELLER K, ZELTSER D. Pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005;111:171-176.
2. ELMING H, SONNE J, LUBLIN HKF. The importance of the QT interval: a review of the literature. Acta Psychiatr Scand 2003;107:96-101.
3. RODEN DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-1022.
4. WITCHEL HJ, HANCOX JC, NUTT DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003;23:58-77.
5. TAYLOR DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003;107:85-95.
6. ZAREBA W, LIN DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003;74:291-306.
7. GLASSMAN AH, BIGGER JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782.
8. NATTEL S, QUANTZ MA. Pharmacological response of quinidine induced early after depolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res 1988;11:808-817.
9. IMRAN N, RAMPES H, ROSEN S. Antipsychotic induced prolongation of QTc interval treated with magnesium. J Psychopharmacol 2003;3:346-349.
10. MEENAGH C, MULHOLLAND C, RYAN MF. Magnesium homeostasis and antipsychotic-induced QTc prolongation. J Psychopharmacol 2004;3:438-439.
11. PRIORI SG, NAPOLITANO C, SCHWARTZ PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;4:529-533.
12. RAY WA, MEREDITH S, THAPA PB et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167.
13. REILLY JG, AYIS A, FERRIER IN et al. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002;180:515-522.
14. HENNESSY S, BILKER WB, KNAUSS JS et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. Br Med J 2002;325:1070-1072.
15. STRAUS SMJM, BLEUMINK GS, DIELEMAN JP et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-1297.
16. CHONG SA, MYTHILY LA, GOH HY. Prolonged QTc intervals in medicated patients with schizophrenia. Hum Psychopharmacol 2003;18:647-649.
17. LIN CH, CHEN MC, WANG SY, LIN CY. Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J Formos Med Assoc 2004;103:437-441.
18. TITIER K, CANAL M, DERIDET E et al. Determination of myocardium to plasma concentration rations of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004;199:52-60.
19. WILTON LV, HEELEY EL, PICKERING RM, SHAKIR SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-126.